Procel, an anti PD-L1 CAR γδ T cell technology, was designed to be used as a stand-alone treatment as well as in combination with a standard anti-tumor modality, and began phase 2 clinical trials in the second quarter of 2023 [221]. Here, CD274 is linked to neoplasm.